June 24, 2020 / 11:22 AM / 19 days ago

BRIEF-Soligenix Completes Enrollment In Phase 3 Clinical Trial Of Sgx942 For Treatment Of Oral Mucositis

June 24 (Reuters) - Soligenix Inc:

* SOLIGENIX COMPLETES ENROLLMENT IN ITS PIVOTAL PHASE 3 CLINICAL TRIAL OF SGX942 FOR THE TREATMENT OF ORAL MUCOSITIS

* SOLIGENIX INC - FINAL TOP-LINE RESULTS EXPECTED Q4 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below